Clinical trial
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of…
NCT00171587 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00171587 |
|---|---|
| Title | Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer |
| Official title | A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer |
| Lead sponsor | Novartis, Industry |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | PTK787/ZK 222584 (vatalanib) |
| Enrollment | 22 |
| Start date | May 1, 2002 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 19, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: